These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 16055621

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
    McLaughlin VV.
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study.
    Kemp K, Savale L, O'Callaghan DS, Jaïs X, Montani D, Humbert M, Simonneau G, Sitbon O.
    J Heart Lung Transplant; 2012 Feb; 31(2):150-8. PubMed ID: 22138355
    [Abstract] [Full Text] [Related]

  • 5. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil.
    Launay D, Sitbon O, Le Pavec J, Savale L, Tchérakian C, Yaïci A, Achouh L, Parent F, Jais X, Simonneau G, Humbert M.
    Rheumatology (Oxford); 2010 Mar; 49(3):490-500. PubMed ID: 20015974
    [Abstract] [Full Text] [Related]

  • 6. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
    Denton CP, Humbert M, Rubin L, Black CM.
    Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
    [Abstract] [Full Text] [Related]

  • 7. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil.
    Barst RJ, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C, Rubin LJ.
    Eur Respir J; 2006 Dec; 28(6):1195-203. PubMed ID: 16899485
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
    Johnson RF, Loyd JE, Mullican AL, Fink CA, Robbins IM.
    J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
    [Abstract] [Full Text] [Related]

  • 9. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N, Frost AE.
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [Abstract] [Full Text] [Related]

  • 10. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
    Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, Rubin LJ, Horn EM, Manes A, Simonneau G.
    Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effectiveness of transition from intravenous epoprostenol to oral/inhaled targeted pulmonary arterial hypertension therapy in pediatric idiopathic and familial pulmonary arterial hypertension.
    Melnick L, Barst RJ, Rowan CA, Kerstein D, Rosenzweig EB.
    Am J Cardiol; 2010 May 15; 105(10):1485-9. PubMed ID: 20451700
    [Abstract] [Full Text] [Related]

  • 13. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.
    J Am Coll Cardiol; 2010 May 04; 55(18):1915-22. PubMed ID: 20430262
    [Abstract] [Full Text] [Related]

  • 14. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects.
    Sitbon O, Beghetti M, Petit J, Iserin L, Humbert M, Gressin V, Simonneau G.
    Eur J Clin Invest; 2006 Sep 04; 36 Suppl 3():25-31. PubMed ID: 16919007
    [Abstract] [Full Text] [Related]

  • 15. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
    Lunze K, Gilbert N, Mebus S, Miera O, Fehske W, Uhlemann F, Mühler EG, Ewert P, Lange PE, Berger F, Schulze-Neick I.
    Eur J Clin Invest; 2006 Sep 04; 36 Suppl 3():32-8. PubMed ID: 16919008
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ.
    J Am Coll Cardiol; 2006 Oct 03; 48(7):1433-7. PubMed ID: 17010807
    [Abstract] [Full Text] [Related]

  • 19. Effects of long-term bosentan in children with pulmonary arterial hypertension.
    Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, Abman SH, Morganti A, Nguyen N, Barst RJ.
    J Am Coll Cardiol; 2005 Aug 16; 46(4):697-704. PubMed ID: 16098438
    [Abstract] [Full Text] [Related]

  • 20. Bosentan.
    Chin K, Channick R.
    Expert Rev Cardiovasc Ther; 2004 Mar 16; 2(2):175-82. PubMed ID: 15151466
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.